JSB462 not checked

Novartis · ARV-766

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
5 active
5 in total · 3 in the EU
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“JSB462 is administered orally, daily and continuously (100 mg or 300 mg QD) until disease progression per PCWG3-modified RECIST 1.1 as assessed by the investigator, the occurrence of unacceptable toxicities, death, participant decision or investigator decision.”In the company’s words, NCT06991556 on ClinicalTrials.gov
Tested for
Metastatic Hormone-sensitive Prostate Cancer, Prostatic Cancer, Castration-Resistant, Prostate Cancer Metastatic, Progressive Metastatic Castrate Resistant Prostate Cancer, Metastatic Prostate Cancer (mCRPC)
Main trialPhase 2
“This Phase II study aims to evaluate efficacy and safety of the combination of JSB462 (also known as luxdegalutamide) at 100 mg and 300 mg once a day (QD) doses + abiraterone compared with an androgen receptor pathway inhibitor (ARPI, abiraterone or enzalutamide) in participants with metastatic Hormone Sensitive Prostate Cancer (mHSPC) and to select the recommended dose of the combination for phase III. Towards that end, the totality of the efficacy, safety, tolerability and PK data from participants randomized in the study will be evaluated”In the company’s words, NCT06991556 on ClinicalTrials.gov
Other names
luxdegalutamide · ARV-766

Other drugs for Metastatic Hormone-sensitive Prostate Cancer

All 29 drugs for Metastatic Hormone-sensitive Prostate Cancer

Coming up5

Changes1

Last 90 days

Trials5

TrialPhaseCompletesWhat it tests
Phase 2Active, not recruiting 3 Dec 2026 An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Phase 2Active, not recruiting 16 Jul 2027 A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
Phase 1/2Active, not recruiting 25 May 2027 A Study of ARV-766 Given by Mouth in Men With Metastatic Prostate Cancer
Phase 1/2Recruiting 9 Nov 2029 An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)
Phase 1Active, not recruiting 29 Jan 2027 A Phase I Study of JSB462 (Luxdegalutamide) in Japanese Patients With Metastatic Prostate Cancer
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow JSB462

Following is part of Solo: you see every change to JSB462 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in